| Literature DB >> 33808737 |
Sajad Fakhri1, Akram Yarmohammadi2, Mostafa Yarmohammadi2, Mohammad Hosein Farzaei3, Javier Echeverria4.
Abstract
In recent decades, several neuroprotective agents have been provided in combating neuronal dysfunctions; however, no effective treatment has been found towards the complete eradication of neurodegenerative diseases. From the pathophysiological point of view, growing studies are indicating a bidirectional relationship between gut and brain termed gut-brain axis in the context of health/disease. Revealing the gut-brain axis has survived new hopes in the prevention, management, and treatment of neurodegenerative diseases. Accordingly, introducing novel alternative therapies in regulating the gut-brain axis seems to be an emerging concept to pave the road in fighting neurodegenerative diseases. Growing studies have developed marine-derived natural products as hopeful candidates in a simultaneous targeting of gut-brain dysregulated mediators towards neuroprotection. Of marine natural products, carotenoids (e.g., fucoxanthin, and astaxanthin), phytosterols (e.g., fucosterol), polysaccharides (e.g., fucoidan, chitosan, alginate, and laminarin), macrolactins (e.g., macrolactin A), diterpenes (e.g., lobocrasol, excavatolide B, and crassumol E) and sesquiterpenes (e.g., zonarol) have shown to be promising candidates in modulating gut-brain axis. The aforementioned marine natural products are potential regulators of inflammatory, apoptotic, and oxidative stress mediators towards a bidirectional regulation of the gut-brain axis. The present study aims at describing the gut-brain axis, the importance of gut microbiota in neurological diseases, as well as the modulatory role of marine natural products towards neuroprotection.Entities:
Keywords: gut-brain axis; marine natural products; neuroprotection; pharmacology; signaling pathway; therapeutic target
Year: 2021 PMID: 33808737 PMCID: PMC8003567 DOI: 10.3390/md19030165
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Gut-brain axis in neurodegenerative diseases and associated outcomes.
| Neurological | Changes of Microbiota | Effects/Outcomes | Reference |
|---|---|---|---|
| AD | ↑TLRs, ↑NF-κB, ↑IL-1β, ↑IL-18, ↑ Aβ, ↑caspase-1, CXCL2, ↑bacterial LPS, | [ | |
| PD |
| ↑TLR4, ↑IL-1β, ↑IL-2, ↑IL-4, ↑IL-6, ↑IL-13, ↑IL-18, ↑IFN-γ, ↑TNF-α | [ |
| ASD |
| ↑mTOR, ↑TNF-α, ↑IL-4, ↑IL-5, ↑IL-6, ↑IL-8, ↑valeric acid, ↑intestinal serotonin, ↓IL-10, ↓TGF-β, ↓fecal acetic acid and butyrate, | [ |
| Depression |
| ↓GABA, ↓dopamine, ↓5-HT, ↓BDNF, ↓IL-10 | [ |
| ALS |
| Dysregulated levels of NO, GABA, LPS, AMPA/NMDA, and oxidative pathways | [ |
| MS | ↓5-HT, ↓dopamine, dysregulated GABA, ↑IFN- | [ | |
| ASD |
| ↑mTOR, ↑TNF-α, ↑IL-4, ↑IL-5, ↑IL-6, ↑IL-8, ↑valeric acid, ↑intestinal serotonin, ↓IL-10, ↓TGF-β, ↓fecal acetic acid and butyrate, | [ |
Aβ: amyloid-beta, AD: Alzheimer’s disease, ALS: amyotrophic lateral sclerosis, ASD: autism spectrum disorder, BDNF: brain-derived neurotrophic factor, CXCL2: chemokine (C-X-C motif) ligand 2, GABA: γ-aminobutyric acid, IFN-γ: interferon-gamma, IL: interleukin, LPS: lipopolysaccharide, MCP: monocyte chemoattractant protein, MIP: macrophage inflammatory protein, MS: multiple sclerosis, mTOR: mammalian target of rapamycin, NF-κB: nuclear factor-κB, NLRP3: NLR family pyrin domain containing 3, NMDA: N-methyl-D-aspartate, PD: Parkinson’s disease, TGF-β: transforming growth factor-beta, TLR: toll-like receptor, TNF-α: tumor necrosis factor-alpha, 5-HT: serotonin.
Figure 1Chemical structure of candidate marine natural products.
Marine-derived compounds, sources, and associated neuroprotective responses.
| Marine Class | Compound | Major Source | Effect/Outcome | Reference |
|---|---|---|---|---|
| Carotenoid | Fucoxanthin |
| ↑BDNF, ↑SOD, ↓ROS, ↓MDA, ↓cleaved caspase-3, ↑Bcl-2/Bax ratio | [ |
| ↓ROS, ↑Beclin-1 (Atg6), ↑LC3 (Atg8) and ↓p62, ↓cleaved caspase-3, ↑HO-1, ↑NQO-1↑Nrf2 | [ | |||
| Astaxanthin | ↓Bax/Bcl-2 ratio, ↓caspase-3, ↓Ca2+ influx, ↓ROS, ↓MDA, ↓LPO, ↓IL-1β, ↓TNF-α, ↓OS, ↓ NF-κB, ↓IL-1β, ↓ICAMs1 | [ | ||
| Lycopene | ↑GSH/GSSG, ↑BDNF, ↓TNF-α, ↓NF-κB, ↓ILs, ↓TLR4 | [ | ||
| Phytosterol | Fucosterol |
| ↑TrkB-mediated ERK1/2, ↓GRP78 ↑BDNF, | [ |
| Solomonsterol A |
| ↓Arthritic score in anti-type II collagen, antibody-induced arthritis mice model | [ | |
| Polysaccharide | Sulfated polysaccharide |
| ↓IgE level in tropomyosin-induced mouse | [ |
| Fucoidan | ↑p-PKC, ↓OS | [ | ||
| Chitosan | Species of crustaceous and cephalopods | Modulating mitochondrial-dependent pathway | [ | |
| Laminarin | Brown seaweeds such as | ↓Pro-inflammatory microglia | [ | |
| Alginate | Microalgae | ↓TLR4, ↓NF-κB, ↓ROS | [ | |
| Diterpene | Excavatolide B |
| ↓iNOS, ↓COX-2 | [ |
| Crassumol E | Soft coral | ↓NF-κB, ↓TNF-α | [ | |
| Lobocrasol | Soft coral | ↓NF-κB | [ | |
| Hydroquinone | Zonarol |
| ↑NQO-1, ↑HO-1, ↑PRDX4 | [ |
| Macrolactin | Macrolactin A | ↑Nrf2, ↑HO-1, | [ | |
| Alkaloid | Neoechinulin B | ↓NF-κB, ↓p38 MAPK | [ |
APP: amyloid-beta precursor protein, BDNF: brain-derived neurotrophic factor, ERK: extracellular-regulated kinase, GPx: glutathione peroxidase, GSH: glutathione, HO-1: heme oxygenase-1, ICAMs-1: soluble intercellular adhesion molecule 1, iNOS: inducible nitric oxide synthase, LC3: light chain 3, MAPK: mitogen-activated protein kinase, MDA: malondialdehyde, Ngb: neuroglobin, NO: nitric oxide, NF-κB: nuclear factor-κB, NQO-1: NAD(P)H Quinone Dehydrogenase 1, Nrf2: nuclear factor erythroid 2–related factor 2, OS: oxidative stress, PKC: protein kinase C, ROS: reactive oxygen species, SOD: superoxide dismutase, TLR: toll-like receptor, TNF-α: tumor necrosis factor-alpha, TrkB: tropomyosin-related kinase receptor B.
Figure 2Marine natural products and gut-brain axis. BDNF: brain-derived neurotrophic factor, MAMPs: microbes associated molecular patterns, PI3K: phosphoinositide 3-kinase, TLRs: tool-like receptors.